help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goodman-Gruen, D.
Right arrow Articles by Barrett-Connor, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goodman-Gruen, D.
Right arrow Articles by Barrett-Connor, E.

Journal of Clinical Endocrinology & Metabolism, Vol 81, 4268-4271, Copyright © 1996 by Endocrine Society

ARTICLES

Effect of replacement estrogen on insulin-like growth factor-I in postmenopausal women: the Rancho Bernardo Study

D Goodman-Gruen and E Barrett-Connor
Department of Family and Preventive Medicine, University of California San Diego, La Jolla 92093-0631C, USA.

Insulin-like growth factor-I (IGF-I) is associated with protein, carbohydrate, and bone metabolism. Results of previous studies examining the effect of exogenous estrogen on levels of IGF-I have been inconsistent. We examined the cross-sectional association between serum IGF-I levels and hormone replacement therapy (HRT) use in 672 postmenopausal women aged 50 yr and older. The mean age-adjusted IGF-I level was highest in the 415 women who reported never or past HRT use (126.8 micrograms/L), lowest in the 128 women who reported using estrogen alone (99.3 micrograms/L), and intermediate in the 115 women who reported using combination estrogen and progesterone (112.4 micrograms/L). A significant linear decline in mean age-adjusted IGF-I levels by duration of HRT use among all current users was seen. The decrease in serum IGF-I with current use of HRT is not consistent with the fact that both HRT and increased levels of IGF-I have been associated with improved glucose and bone metabolism and lipid profile. Further research is needed to evaluate the effect of the addition of a progestin to oral HRT on IGF-I-induced changes in GH levels.


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
R. J. Cleveland, M. D. Gammon, S. N. Edmiston, S. L. Teitelbaum, J. A. Britton, M. B. Terry, S. M. Eng, A. I. Neugut, R. M. Santella, and K. Conway
IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project
Carcinogenesis, April 1, 2006; 27(4): 758 - 765.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
K.-C. Leung, G. Johannsson, G. M. Leong, and K. K. Y. Ho
Estrogen Regulation of Growth Hormone Action
Endocr. Rev., October 1, 2004; 25(5): 693 - 721.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
J. M. Fitts, R. M. Klein, and C. A. Powers
Comparison of Tamoxifen and Testosterone Propionate in Male Rats: Differential Prevention of Orchidectomy Effects on Sex Organs, Bone Mass, Growth, and the Growth Hormone-IGF-I Axis
J Androl, July 1, 2004; 25(4): 523 - 534.
[Abstract] [Full Text] [PDF]

Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
D. L. Waters, C. L. Yau, G. D. Montoya, and R. N. Baumgartner
Serum Sex Hormones, IGF-1, and IGFBP3 Exert a Sexually Dimorphic Effect on Lean Body Mass in Aging
J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2003; 58(7): M648 - 652.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. D. Holmes, M. N. Pollak, and S. E. Hankinson
Lifestyle Correlates of Plasma Insulin-like Growth Factor I and Insulin-like Growth Factor Binding Protein 3 Concentrations
Cancer Epidemiol. Biomarkers Prev., September 1, 2002; 11(9): 862 - 867.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
V. Sacchini, S. Zurrida, G. Andreoni, A. Luini, V. Galimberti, P. Veronesi, M. Intra, G. Viale, and U. Veronesi
Pathologic and Biological Prognostic Factors of Breast Cancers in Short- and Long-Term Hormone Replacement Therapy Users
Ann. Surg. Oncol., April 1, 2002; 9(3): 266 - 271.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
W. M. Drake, S. J. Howell, J. P. Monson, and S. M. Shalet
Optimizing GH Therapy in Adults and Children
Endocr. Rev., August 1, 2001; 22(4): 425 - 450.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Byrne, G. A. Colditz, W. C. Willett, F. E. Speizer, M. Pollak, and S. E. Hankinson
Plasma Insulin-like Growth Factor (IGF) I, IGF-binding Protein 3, and Mammographic Density
Cancer Res., July 1, 2000; 60(14): 3744 - 3748.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. M. Fitts, R. M. Klein, and C. A. Powers
Comparison of Tamoxifen Effects on the Actions of Triiodothyronine or Growth Hormone in the Ovariectomized-Hypothyroid Rat
J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 392 - 402.
[Abstract] [Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Paassilta, K. Kervinen, M. Linnaluoto, and Y. A. Kesaniemi
Alcohol Withdrawal–Induced Change in Lipoprotein(a) : Association With the Growth Hormone/Insulin-like Growth Factor-I (IGF-I)/IGF-Binding Protein-1 (IGFBP-1) Axis
Arterioscler. Thromb. Vasc. Biol., April 1, 1998; 18(4): 650 - 654.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1996 by The Endocrine Society